CYP19A1 and metastatic neoplasm: The decreased PFS compared with the historic data may be explained by prior endocrine treatment for metastatic disease in this patient population: 93 (71%) patients had prior aromatase inhibitor (AI), 33 (25.2%) patients had prior fulvestrant, 2 (1.5%) patients had prior tamoxifen, and only 3 (2.3%) patients were endocrine therapy naive.